JP2023549341A5 - - Google Patents

Info

Publication number
JP2023549341A5
JP2023549341A5 JP2023527451A JP2023527451A JP2023549341A5 JP 2023549341 A5 JP2023549341 A5 JP 2023549341A5 JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023527451 A JP2023527451 A JP 2023527451A JP 2023549341 A5 JP2023549341 A5 JP 2023549341A5
Authority
JP
Japan
Prior art keywords
pyrazino
piperidine
methyl
hydroxyphenyl
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023527451A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023549341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058424 external-priority patent/WO2022099117A1/en
Publication of JP2023549341A publication Critical patent/JP2023549341A/ja
Publication of JP2023549341A5 publication Critical patent/JP2023549341A5/ja
Pending legal-status Critical Current

Links

JP2023527451A 2020-11-06 2021-11-08 Brm標的化化合物及び関連する使用方法 Pending JP2023549341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063110688P 2020-11-06 2020-11-06
US63/110,688 2020-11-06
PCT/US2021/058424 WO2022099117A1 (en) 2020-11-06 2021-11-08 Brm targeting compounds and associated methods of use

Publications (2)

Publication Number Publication Date
JP2023549341A JP2023549341A (ja) 2023-11-24
JP2023549341A5 true JP2023549341A5 (cg-RX-API-DMAC10.html) 2024-11-18

Family

ID=81456756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023527451A Pending JP2023549341A (ja) 2020-11-06 2021-11-08 Brm標的化化合物及び関連する使用方法

Country Status (10)

Country Link
US (1) US12448389B2 (cg-RX-API-DMAC10.html)
EP (1) EP4240743A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023549341A (cg-RX-API-DMAC10.html)
KR (1) KR20230117577A (cg-RX-API-DMAC10.html)
CN (1) CN116745295A (cg-RX-API-DMAC10.html)
AU (1) AU2021376415A1 (cg-RX-API-DMAC10.html)
CA (1) CA3200685A1 (cg-RX-API-DMAC10.html)
IL (1) IL302669A (cg-RX-API-DMAC10.html)
MX (1) MX2023005301A (cg-RX-API-DMAC10.html)
WO (1) WO2022099117A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
US20240024488A1 (en) * 2020-11-20 2024-01-25 Foghorn Therapeutics Inc. Compounds and uses thereof
CA3211347A1 (en) 2021-03-19 2022-09-22 Erika Araujo Indazole based compounds and associated methods of use
JP2024539269A (ja) * 2021-10-22 2024-10-28 グルータクス セラピューティクス (シャンハイ) カンパニー、リミテッド Crbn e3リガーゼリガンド化合物、当該リガンド化合物に基づいて開発したタンパク質分解剤及びそれらの応用
PL4245756T3 (pl) * 2022-03-17 2025-02-17 Gilead Sciences, Inc. Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体
EP4587127A1 (en) * 2022-09-15 2025-07-23 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
US20240190886A1 (en) * 2022-11-15 2024-06-13 Prelude Therapeutics Incorporated BRM Targeting Compounds and Associated Methods of Use
WO2024192064A1 (en) * 2023-03-14 2024-09-19 Oncopia Therapeutics, Inc. D/B/A/ Proteovant Therapeutics, Inc. Compounds and compositions as smarca2/4 degraders and uses thereof
CN120957992A (zh) * 2023-04-07 2025-11-14 南京再明医药有限公司 Brm选择性降解剂化合物
EP4695250A1 (en) 2023-04-12 2026-02-18 Aurigene Oncology Limited Tetracyclic compounds as smarca2 and/or smarca4 degraders
AU2024304006A1 (en) * 2023-06-16 2026-01-08 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
WO2025101738A1 (en) * 2023-11-07 2025-05-15 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
WO2025106482A1 (en) * 2023-11-13 2025-05-22 Oncopia Therapeutics, Inc. D/B/A Sk Life Science Labs Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025106472A1 (en) * 2023-11-13 2025-05-22 Regents Of The University Of Michigan Compounds and compositions as smarca2/4 degraders and uses thereof
WO2025113460A1 (zh) * 2023-11-28 2025-06-05 西藏海思科制药有限公司 一种哒嗪并三环衍生物及其在医药上的应用
AU2024411627A1 (en) * 2023-12-26 2026-07-16 Gluetacs Therapeutics (Shanghai) Co., Ltd. Compounds with two azaheterocycles substituted isoindolinone skeleton and uses thereof
WO2025184459A1 (en) * 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting compounds and associated methods of use
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025194405A1 (en) * 2024-03-21 2025-09-25 Prelude Therapeutics Incorporated Polymorphic smarca inhibitors and uses thereof
WO2026098598A1 (zh) * 2024-11-08 2026-05-15 正大天晴药业集团股份有限公司 含有三并杂环的化合物
WO2026136866A1 (en) 2024-12-20 2026-06-25 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2026151924A1 (en) * 2025-01-09 2026-07-16 Triana Biomedicines, Inc. 2-(2, 6-dioxopiperidine-3-yl)-1, 3-dioxoisoindoline derivatives bearing an heteroaryl group as anaplastic lymphoma kinase (alk) degraders and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657744A (en) 1970-05-08 1972-04-25 Univ Minnesota Method for fixing prosthetic implants in a living body
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5040548A (en) 1989-06-01 1991-08-20 Yock Paul G Angioplasty mehtod
US5350395A (en) 1986-04-15 1994-09-27 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US5061273A (en) 1989-06-01 1991-10-29 Yock Paul G Angioplasty apparatus facilitating rapid exchanges
US4748982A (en) 1987-01-06 1988-06-07 Advanced Cardiovascular Systems, Inc. Reinforced balloon dilatation catheter with slitted exchange sleeve and method
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
CA1322628C (en) 1988-10-04 1993-10-05 Richard A. Schatz Expandable intraluminal graft
US6344053B1 (en) 1993-12-22 2002-02-05 Medtronic Ave, Inc. Endovascular support device and method
US5674278A (en) 1989-08-24 1997-10-07 Arterial Vascular Engineering, Inc. Endovascular support device
US5292331A (en) 1989-08-24 1994-03-08 Applied Vascular Engineering, Inc. Endovascular support device
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート,インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
GB2554071A (en) 2016-09-14 2018-03-28 Univ Dundee Small molecules
SI3526202T1 (sl) 2016-10-11 2025-04-30 Arvinas Operations, Inc. Spojine in postopki za ciljno razgradnjo androgenskih receptorjev
IL266842B (en) 2016-12-01 2022-09-01 Arvinas Operations Inc History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
AU2019249849C1 (en) 2018-04-01 2022-09-29 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
SG11202104495YA (en) * 2018-04-26 2021-05-28 Aurigene Discovery Tech Ltd Pyridazine derivatives as smarca2/4 degraders
WO2019213005A1 (en) * 2018-04-30 2019-11-07 Dana-Farber Cancer Institute, Inc. Small molecule degraders of polybromo-1 (pbrm1)
US12454520B2 (en) * 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
EP3867242A1 (en) 2018-10-15 2021-08-25 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
WO2021133917A1 (en) * 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
PT4161935T (pt) * 2020-06-09 2025-08-14 Prelude Therapeutics Inc Compostos direcionados a brm e métodos de utilização associados
JP2025521091A (ja) * 2022-05-10 2025-07-08 プレリュード・セラピューティクス・インコーポレイテッド がんの治療のためのsmarca4タンパク質分解因子としての6,6a,7,8,9,10-ヘキサヒドロ-5h-ピラジノ[1’,2’:4,5]ピラジノ[2,3-c]ピリダジン誘導体

Similar Documents

Publication Publication Date Title
JP7313354B2 (ja) Tlr阻害剤として有用なアミド置換されたインドール化合物
US12448389B2 (en) BRM targeting compounds and associated methods of use
TWI689510B (zh) 4-氮雜吲哚化合物
AU2015261812B2 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
US20240245681A1 (en) Heterocyclic derivatives useful as shp2 inhibitors
JP5788415B2 (ja) Cdk4/6阻害剤としてのピロロピリミジン化合物
CN113795483A (zh) 作为shp2拮抗剂的甲酰胺-嘧啶衍生物
IL280331B2 (en) Heterobicyclic compounds for inhibiting the activity of shp2
AU2018239542A1 (en) Novel heterocyclic derivatives useful as SHP2 inhibitors
KR20200100760A (ko) 디아자인돌 화합물
EP3661934A1 (en) [1,2,4]TRIAZOLO[4,3-a]PYRIDINYL SUBSTITUTED INDOLE COMPOUNDS
KR20200100687A (ko) 치환된 인돌 에테르 화합물
TW202330548A (zh) 用於降解egfr激酶的化合物
CN116981661A (zh) 稠环取代的六元杂环化合物及其制法和用途
US12091426B2 (en) Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
EP4051388A1 (en) Substituted pyrazole compounds as toll receptor inhibitors
JP6454346B2 (ja) 芳香族複素環式化合物及び医薬におけるその応用
JP2025530791A (ja) トリアジン化合物及びその使用
WO2025253326A1 (ko) Kras 저해제로서 신규한 3환 화합물 및 이의 용도
RU2014144285A (ru) Карбоксамидные соединения и их применение в качестве ингибиторов кальпаина v
JP2015512427A5 (cg-RX-API-DMAC10.html)
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
CN115557946A (zh) 杂环内酰胺类化合物,包含其的药物组合物及其用途
EA052189B1 (ru) Соединения, нацеленные на brm, и связанные с ними способы использования